Results 41 to 50 of about 47,533 (300)
The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer [PDF]
Frontiers in Molecular Biosciences, 2021 BackgroundColorectal cancer (CRC) is estimated to be one of the most common cancers and the leading cause of cancer-related death worldwide. SOX9 is commonly overexpressed in CRC and participates in drug resistance. In addition, DNA damage repair confers resistance to anticancer drugs.
Yiqiang Liu +13 more
openaire +3 more sources
BMC Cancer, 2020 Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao +9 more
doaj +1 more source
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]
, 2006 Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim +58 more
core +2 more sources
Frontiers in Oncology, 2021 Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the
Qiu Lin, Li Luo, Hua Wang
doaj +1 more source
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal +7 more
core +2 more sources
Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]
, 2009 The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Davey, Ross, Stordal, Britta
core +2 more sources
Cell Death and Disease, 2021 Long noncoding RNAs (lncRNAs) have emerged as a new class of regulatory molecules implicated in therapeutic resistance, yet the mechanisms underlying lncRNA-mediated oxaliplatin resistance in colorectal cancer (CRC) are poorly understood.
Xuan Deng +11 more
doaj +1 more source
Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]
, 2019 Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan +6 more
core +1 more source
Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance [PDF]
ecancermedicalscience, 2010 Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly ...
Seetharam, RN, Sood, A, Goel, S
openaire +2 more sources
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source